Literature DB >> 12953804

Apoptotic signaling in multiple myeloma: therapeutic implications.

Dharminder Chauhan1, Teru Hideshima, Kenneth C Anderson.   

Abstract

Fifteen thousand new cases of multiple myeloma (MM) will occur in the United States in 2003, and the disease remains incurable. Diverse classes of chemotherapeutic agents induce cell death or apoptosis in MM cells; however, prolonged drug exposures ultimately induce chemoresistance. The mechanisms whereby MM cells resist drugs include alterations in intracellular signaling as well as adherence and cytokines in the bone marrow (BM) microenvironment. Novel agents that target the MM cell in its BM microenvironment are needed to both enhance anti-MM activity and prevent development of drug resistance. Delineation of cellular growth and apoptotic signaling pathways in MM cells may identify molecules that serve as novel therapeutic targets on the basis of interruption of MM cell growth or triggering of MM cell death.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12953804     DOI: 10.1007/BF02983378

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  67 in total

1.  Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone.

Authors:  P Tassone; S Forciniti; E Galea; R Savino; M C Turco; P Iacopino; P Tagliaferri; G Morrone; G Ciliberto; S Venuta
Journal:  Cell Death Differ       Date:  2000-03       Impact factor: 15.828

2.  Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis.

Authors:  S Matsuyama; J Llopis; Q L Deveraux; R Y Tsien; J C Reed
Journal:  Nat Cell Biol       Date:  2000-06       Impact factor: 28.824

3.  Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells.

Authors:  J M Grad; N J Bahlis; I Reis; M M Oshiro; W S Dalton; L H Boise
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

4.  Homotypic cell aggregations of human myeloma cells with ICAM-1 and LFA-1 molecules.

Authors:  M M Kawano; N Huang; H Tanaka; H Ishikawa; A Sakai; O Tanabe; M Nobuyoshi; A Kuramoto
Journal:  Br J Haematol       Date:  1991-12       Impact factor: 6.998

Review 5.  Cell death: the significance of apoptosis.

Authors:  A H Wyllie; J F Kerr; A R Currie
Journal:  Int Rev Cytol       Date:  1980

6.  Humanized anti-interleukin-6 receptor monoclonal antibody induced apoptosis of fresh and cloned human myeloma cells in vitro.

Authors:  Toshiyuki Hirata; Chihiro Shimazaki; Toshiya Sumikuma; Eishi Ashihara; Hideo Goto; Tohru Inaba; Yasuo Koishihara; Masao Nakagawa
Journal:  Leuk Res       Date:  2003-04       Impact factor: 3.156

7.  Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells.

Authors:  S Le Gouill; C Pellat-Deceunynck; J-L Harousseau; M-J Rapp; N Robillard; R Bataille; M Amiot
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

8.  Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

Authors:  Karin Vanderkerken; Evy De Leenheer; Claire Shipman; Kewal Asosingh; Angelo Willems; Ben Van Camp; Peter Croucher
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

9.  Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death.

Authors:  N Zamzami; P Marchetti; M Castedo; D Decaudin; A Macho; T Hirsch; S A Susin; P X Petit; B Mignotte; G Kroemer
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

10.  Chromatin condensation during apoptosis is accompanied by degradation of lamin A+B, without enhanced activation of cdc2 kinase.

Authors:  F A Oberhammer; K Hochegger; G Fröschl; R Tiefenbacher; M Pavelka
Journal:  J Cell Biol       Date:  1994-08       Impact factor: 10.539

View more
  5 in total

1.  Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.

Authors:  Makoto Hamasaki; Teru Hideshima; Pierfrancesco Tassone; Paola Neri; Kenji Ishitsuka; Hiroshi Yasui; Norihiko Shiraishi; Noopur Raje; Shaji Kumar; Donald H Picker; Gary S Jacob; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2005-02-10       Impact factor: 22.113

Review 2.  Apoptosis of multiple myeloma.

Authors:  Marcela Oancea; Aruna Mani; Mohamad A Hussein; Alexandru Almasan
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

3.  The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.

Authors:  M Staudinger; P Glorius; R Burger; C Kellner; K Klausz; A Günther; R Repp; W Klapper; M Gramatzki; M Peipp
Journal:  Blood Cancer J       Date:  2014-06-13       Impact factor: 9.812

4.  Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials.

Authors:  Chintan Shah; Rohit Bishnoi; Yu Wang; Fei Zou; Harini Bejjanki; Samip Master; Jan S Moreb
Journal:  Oncotarget       Date:  2018-05-04

5.  Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma.

Authors:  Roberta Martiniani; Valentina Di Loreto; Chiara Di Sano; Alessandra Lombardo; Anna Marina Liberati
Journal:  Adv Hematol       Date:  2012-08-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.